Articles On Noxopharm (ASX:NOX)

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

COVID-19 vaccines are driving markets but treatments are where most people believe a solution to the pandemic lies. However, use of the two most famous treatments to date — Gilead Sciences’ HIV drug remdesivir and US President Donald Trump’...

Marking a step forward, clinical-stage drug development company Noxopharm (ASX:NOX) has lodged a pre-IND (Investigational New Drug) submission with the U.S. Food and Drug Administration (FDA) for a Veyonda® clinical trial in COVID-19 (SARS-...

Noxopharm (ASX:NOX) has lodged a pre-Investigational New Drug (pre-IND) submission with the US FDA for a clinical trial of its Veyonda in patients with COVID-19 infection.

Shares in Noxopharm Ltd (ASX:NOX) traded more than 40% higher on Tuesday afternoon after the company received advice from the US Food and Drug Administration (FDA) that it should lodge a pre-Investigational New Drug (pre-IND) submission for...

Noxopharm (ASX:NOX) has announced a $7.9 million capital raise its says will go towards progressing its oncology programs as well as its recent move into infection.

Our summary of Noxopharm Ltd's recent announcement What's happened? Noxopharm Limited (ASX:NOX) announces it will undertake a 1 for 2.5 fully underwritten, pro-rata entitlement offer of new fully paid ordinary shares at an Offer Price of $0...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve keen keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Biotech company Noxopharm Limited (ASX:NOX) possesses an exciting new potential treatment for end-stage prostate cancer as suggested by the latest radiographic review of DARRT-1 clinical study, supporting the Company’s belief in the anti-ca...

In a new development, clinical-stage oncology drug development player Noxopharm Limited (ASX:NOX) has confirmed that an isoflavonoid drug candidate has passed the proof-of-principle test for its brain cancer program in laboratory studies, p...

Noxopharm (ASX:NOX) has released details of the radiographic review of its DARRT-1 clinical study and says it shows a major benefit from a combination of Veyonda and low-dose radiotherapy.

Our summary of Noxopharm Ltd's recent announcement What's happened? Noxopharm Limited (ASX:NOX) today has released details of the radiographic review of its DARRT-1 clinical study. What are the key highlights? The review shows a major be...

Clinical-stage Australian oncology drug development player Noxopharm (ASX:NOX) has revealed that the active ingredient in Veyonda® - idronoxil, blocks the STING (Stimulator of Interferon Genes) signalling pathway associated with the type of...

Biotech company Noxopharm (ASX: NOX) will seek approval from the US Food and Drug Administration for a clinical study involving its end-stage prostate cancer drug Veyonda on early-stage COVID-19 patients with the aim of blocking the progres...

Noxopharm (ASX:NOX) is the latest biotech to announce it will test its drug against COVID-19. So how exactly does an anti-prostate cancer drug work for COVID-19? Noxopharm says it is all about one signalling pathway — the STING (Stimulator...

Noxopharm (NOX:ASX) has announced the active ingredient of its investigational therapy Veyonda - idronoxil - could block the hyper-inflammation stemming from the infection that is believed responsible for deaths in patients with COV...

Australian oncology drug development company Noxopharm (ASX:NOX), along with the Hudson Institute of Medical Research in Melbourne, has identified anti-inflammatory properties of idronoxil, consistent with reducing a ‘cytokine storm’ whic.....

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Noxopharm (ASX: NOX) is the latest small cap to reveal it has a potential COVID-19 treatment, after it reported this morning its advanced idronoxil drug could block an excessive inflammatory response believed to be responsible for many COVI...

Australian clinical stage drug development company Noxopharm Limited (ASX:NOX) recently announced a significant milestone, that its potentially transformative anti-cancer drug candidate Veyonda® has been awarded first allowed patent applica...

Noxopharm (ASX:NOX) has announced that the last patient has been enrolled and safely dosed in the ongoing LuPIN Phase 1/2 clinical trial being conducted by St Vincent’s Hospital Sydney.

CEO Graham Kelly PhD said, “Bringing Veyonda to market for late-stage prostate cancer remains our commercial imperative. This IND grant for a less common cancer type contributes to that overall commercial objective in several ways."...

Mirroring the wider market, many of the small cap IPOs completed so far in 2020 have white-knuckled their way through the opening months of the new decade. Only two – COSOL and Cobre – made solid gains. The rest bounced around like a House...

Latest LuPIN Trial Interim Results and an Alliance with Oncology Services Provider, GenesisCare Further Enhance Veyonda®’s Potential Commercial and Shareholder Value  Australian clinical-stage drug development company Noxopharm Limite...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Noxopharm (ASX:NOX) has announced a new clinical alliance with oncology services provider GenesisCare to offer a compassionate access program with its novel lead product candidate, Veyonda.

Nyrada was established in 2017 to advance the non-oncology assets developed by Noxopharm, leaving Noxopharm free to concentrate on the development of Veyonda.

Sydney biotech company Nyrada has made its debut on the ASX in the first float of the year following an $8.5 million initial public offering.

It was a solid debut for drug manufacturer Nyrada (ASX:NYR) on the ASX this morning. Nyrada raised $8.5m and opened its first session 52.5 per cent higher than its 20c IPO price, hitting an early peak of 30.5c.   Nyrada is a spin off of f...

Following an oversubscribed IPO, Noxopharm’s (NOX) U.S. spin-off Nyrada has listed on the ASX under the code NYR Post-listing, Noxopharm will hold an almost 27 per cent shareholding in Nyrada Nyrada was established in 2017 to help Noxoph...

Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc experienced strong demand in its initial public offering and will now make its ASX debut today after successfully raising $8.5 million under the ticker ‘NYR’. Nyrada was estab...

20 Dec 2019 - Clinical drug development company Noxopharm (ASX:NOX) has released DARRT-1 study clinical data which it says shows strong anti-cancer response in 47% of men with late…

The Boards of Noxopharm (NOX) and Nyrada have received full commitments for the $8.5 million IPO Noxopharm was advised by Lead Manager, Alto Capital that the IPO has been fully allocated and reconciliation of funds are underway Nyrada i...

Antisense Therapeutics (ASX:ANP) jumped over 20 per cent this morning on news its ATL1102 drug, fighting Duchenne Muscular Dystrophy (DMD), delivered strong preliminary results in its clinical trial. The stock is now up 270 per cent over th...

Australian drug development company, Noxopharm Limited (ASX: NOX) recently announced the completion of DARRT-1 Phase 1b study in late-stage prostate cancer, reporting  positive end-of-study data. Following that announcement, NOX shares rose...

Noxopharm Ltd (ASX: NOX), a clinical-stage Australian drug development company, has secured an increase to its existing funding agreement with two New York institutional investors– Lind Global Macro Fund, LP and CST Investment Fund. The ag...

Australian company Noxopharm (ASX:NOX) has reported positive end-of-study data from its DARRT-1 Phase 1b trial of Veyonda.

Biotech drug developer Noxopharm (ASX: NOX) has reported positive end-of-study results from its DARRT-1 Phase 1b trial treating men with late-stage prostate cancer. In an update yesterday, the oncology-focused company announced that clinica...

Australia headquartered clinical stage drug development company, Noxopharm Limited (ASX: NOX) has been in the spotlight for its potentially transformative therapy in late-stage prostate cancer where few or no standard therapy exists current...

Emerging Australian oncology company Noxopharm (ASX:NOX) has used its annual general meeting to update investors on its pipeline.

Clinical-stage drug development company, Noxopharm Limited (ASX: NOX) continues to show  its potentially transformative therapy in late-stage prostate cancer where few or no remaining standard treatment options currently exist. Noxopharm’s...

The company said Mr Hunter’s skills will add important management strength to its executive team as it embarks on its next phase of growth.

Noxopharm Limited (ASX: NOX) has recently provided an update related to the research progress on its key drug candidate Veyonda® which is presently undergoing clinical trials in late-stage, progressive and metastatic, castration-resistant p...

The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies. More than 20 companies will present at the conference on Thursday, Octob...

Sydney-based Noxopharm (ASX:NOX) has updated on interim data from the DARRT-1 study where Veyonda is being tested in patients with prostate cancer which is late-stage, progressive and metastatic.

Drug development company Noxopharm (ASX: NOX) is growing more optimistic about the use of its Veyonda treatment on patients with late-stage prostate cancer. NOX provided an interim update on its DARRT-1 clinical trial, where patients are gi...

Anti-cancer drug developer Noxopharm (ASX: NOX) has set the stage to present its highly-anticipated clinical data to the Clinical Oncology Society of Australia by publishing interim data from a DARRT-1 clinical study using Veyonda to treati...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

16 Oct 2019 - Noxopharm (ASX:NOX) has made some changes to its senior executive and Board structures.